Equities Analysts Offer Predictions for TENX FY2026 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Leerink Partnrs reduced their FY2026 earnings per share (EPS) estimates for shares of Tenax Therapeutics in a note issued to investors on Tuesday, February 4th. Leerink Partnrs analyst D. Risinger now anticipates that the specialty pharmaceutical company will post earnings of ($3.93) per share for the year, down from their previous forecast of ($3.91). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ FY2027 earnings at ($4.17) EPS and FY2028 earnings at ($2.70) EPS.

Several other research analysts have also recently commented on TENX. Guggenheim initiated coverage on shares of Tenax Therapeutics in a report on Monday, October 14th. They set a “buy” rating and a $16.00 target price for the company. Leerink Partners assumed coverage on Tenax Therapeutics in a report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price target for the company. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Stock Up 6.3 %

Shares of NASDAQ TENX opened at $7.07 on Thursday. The firm’s 50-day moving average is $6.12 and its 200-day moving average is $4.74. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $17.00.

Institutional Investors Weigh In On Tenax Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in TENX. Sphera Funds Management LTD. bought a new position in Tenax Therapeutics during the third quarter valued at $101,000. Stonepine Capital Management LLC bought a new stake in Tenax Therapeutics during the third quarter valued at $173,000. Finally, Vestal Point Capital LP purchased a new position in Tenax Therapeutics in the third quarter worth $288,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.